| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Medicine, Medical University of South Carolina and the Medical Research Service, Ralph H. Johnson VA Medical Center, Charleston, SC 29425;
Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262;
Northwestern University Medical School, Chicago, IL 60611;
Department of Pathology, University of Miami School of Medicine, Miami, FL 33125; and
¶
Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Factor B is produced by hepatocytes (6), phagocytes (7, 8), fibroblasts (9), epithelial cells (10), and endothelial cells (11). Bf is an acute phase reactant; therefore, serum levels of Bf increase during inflammation stimulated by cytokines, growth factors, and bacterial products (1, 5). cis elements responsible for the constitutive and regulated expression of Bf are located in the C2-Bf intergenic region (4). Factor B not only is a component of the alternative complement pathway but also serves as a B cell growth factor (12, 13), stimulates mononuclear cell cytotoxicity (14, 15), induces macrophage spreading (16), and solubilizes immune complexes (ICs) (17, 18, 19). Bf is found in glomeruli in immune complex glomerulonephritis (20), is produced by glomeruli during inflammation (20), and forms split products (5). High serum levels of these split products correlate with increased disease activity in systemic lupus erythematosus (5, 21). The role of factor B in disease pathogenesis, however, is unclear (21).
In contrast, the classical pathway of the complement system has a known important role in immune complex glomerulonephritis. ICs depositing in the kidney activate the classical pathway, thus eliciting inflammation and tissue destruction (1, 5, 22). Furthermore, components of the classical complement pathway are important in humoral responses to foreign Ags, immune complex clearance, B cell tolerance, and disposition of apoptotic cells (23, 24, 25, 26, 27). Genetic deficiency of C3 and therapies directed at blocking C3 activity (e.g., Crry transgenic mice) prevent glomerular inflammation and tissue damage in murine models of Ab-induced glomerulonephritis (28, 29, 30, 31, 32).
The role of the complement cascade in disease is not purely proinflammatory, however, as demonstrated by studies of specific complement deficiencies. Deficiencies of some components of the classical complement pathway (e.g., C4 and C1q) are associated with an increased incidence of lupus in humans and lupus-like disease in murine knockout strains (22, 23, 24). Development of lupus-like disease in C4- and C1q-deficient mice appears secondary to defects in B cell tolerance in the former and defects in clearance of apoptotic cells in the latter (23, 26). Thus, the complement cascade has both "protective" actions (i.e., clearance of ICs and apoptotic cells as well as maintenance of B cell tolerance) and "proinflammatory" effects (i.e., production of C5a and terminal complement components). The alternative pathway may enhance disease by amplifying activation of the classical pathway and its proinflammatory effects; however, the effect of the alternative pathway on inflammation and tissue destruction in immune complex glomerulonephritis is to this point unknown.
MRL/MpJ-Faslpr (MRL/lpr) mice spontaneously develop a severe systemic autoimmune disease similar to human lupus (33). As part of their systemic autoimmune disease, MRL/lpr mice produce autoantibodies (anti-DNA and rheumatoid factors (RF)), and cryoglobulins that are pathogenic in the immune complex glomerulonephritis and vasculitis that develop in these mice (33). Glomerular immune deposits in these mice contain IgG, IgM, IgA, Bf, and C3 (20, 33). Thus, MRL/lpr mice are useful murine models for studies of the pathogenesis of spontaneous immune complex-mediated diseases (20, 33, 34, 35).
To determine the role of the alternative complement pathway in autoimmune nephritis, Bf-deficient mice were backcrossed to MRL/lpr mice for four generations. By intercrossing F4 Bf heterozygous mice, we derived MRL/lpr B-/-, B+/-, and B+/+ mice; serologic and clinical disease activity were measured over time. Our results indicate that B-/- mice developed significantly less proteinuria, glomerular IgG deposition, and pathological renal disease than B+/+ or B+/- mice. Compared with the other two groups, significantly lower levels of serum IgG3 RF and cryoglobulins were found in B-/- mice. Serum C3 levels were normal in the B-/- mice compared with significantly decreased levels in the B+/- or B+/+ mice. These findings indicate that Bf plays a key role in the pathogenesis of glomerulonephritis in MRL/lpr mice and that the alternative pathway amplification loop has prominent effects on serum C3 levels in immune complex nephritis.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Factor B-deficient mice were derived as previously described (36). B6/129 B+/- mice were intercrossed for four generations to yield the B-/- mice used in the first crosses with MRL/lpr mice. Offspring of these matings were further backcrossed for three generations to MRL/lpr mice. B+/- backcross four mice were bred to yield the mice used in this study. Eleven B-/-, 14 B+/+ and 10 B+/- mice were included in this study. Mice were maintained in the animal facility of Washington University and the Strom Thurmond Biomedical Research Building at the Medical University of South Carolina under specific pathogen-free conditions. Routine screening of the mice for murine pathogens was negative.
Genotyping of the mice by PCR
Primers for PCR for Bf were as follows: W1398 (5'; Bf) 5'-CCGAAGCATTCCTATCCTCC-3', W1399 (5'; Neo) 5'-CGAATGG GTGACCGCTTCC-3', W1393 (3'; Bf) 5'-GTAGTCTTGTCTGCTTTCTCC-3'. DNA was isolated from tail snips (3- to 4-wk-old mice) using a QIAamp Tissue Kit (Qiagen, Santa Clarita, CA). PCR was performed by adding 2 µl DNA (1 µg) into a 23-µl reaction mixture containing 1.5 mM MgCl2, 6.7 µM concentrations each of oligonucleotide mix, 10 mM concentrations each of dNTP mix, and 0.2 ml of Taq Gold. PCR conditions were as follows: 94°C for 4 min; 28 cycles of 94°C for 1 min, 68°C for 1 min, and 72°C for 2 min; 72°C for 10 min. After PCR amplification, samples were electrophoresed in a 2% agarose gel and visualized by ethidium bromide staining.
Primers for PCR for Fas were as follows: Fas A (5'-AGGTTAC AAAAGGTCACCC-3'), Fas B (5'-GATACGAAGATCCTTTCCTGTG-3'), and Fas C (5'-CAAACGCAGTCAAATCTGCTC-3'). In brief, individual genomic tail DNA was isolated and used in PCR. PCR conditions were as follows: 94°C for 10 min; 40 cycle of 94°C for 1 min, 50°C for 1 min, and 72°C for 1 min; 72°C for 10 min. After PCR amplification, samples were electrophoresed in a 2% agarose gel and visualized by ethidium bromide staining.
MHC typing
H-2 of the mice was determined by flow cytometric analysis of splenic mononuclear cells. Single-cell suspensions were derived and stained with FITC-labeled anti-H-2Dk (mAb KH95) or anti-H-2Db (mAb 15-5-5, PharMingen, San Diego, CA). FITC-labeled isotype control Abs were used to eliminate nonspecific staining as a variable. Samples were analyzed on a Becton Dickinson FACStar machine, and results analyzed with CellQuest software (Becton Dickinson).
To confirm the H-2 genotype, we performed PCR RFLP analysis using the techniques of Peng and Craft (37) specifically designed to differentiate H-2k and H-2b. Briefly, tail DNA was amplified using the primers IAAIF 5'-GAAGACGACATTGAGGCCGACCACGTAGGC-3' and IAAIR 5'-ATTGGTAGCTGGGGTGGAATTTGACCTCTT-3'. PCR was performed with a 12-min denaturation step of 94°C followed by cycles of 94°C for 20 s, 60°C for 1 min, and 72°C for 1 min with a final extension of 10 min at 72°C. The resultant PCR product was digested with HindIII and run on an agarose gel. Amplified DNA of the H-2k genotype is digested whereas DNA of the H-2b genotype is not, allowing differentiation by agarose gel electrophoresis.
Urine protein excretion
Mice were placed in metabolic cages for 24-h urine collection. To prevent bacterial growth, antibiotics (ampicillin, gentamicin, and chloramphenicol) were added to collection tubes. Urinary protein excretion was determined with the Bio-Rad protein assay kit according to the manufacturer’s instructions (Bio-Rad, Hercules, CA) and reported as milligrams of protein per mouse per day.
Measurement of anti-DNA Ab
Anti-DNA levels were measured by ELISA as previously described
(38). Briefly, 96-well ELISA plates were coated with 5
µg/ml double-stranded calf thymus DNA (dsCT DNA) at 37°C overnight.
The plates were then washed with PBS-0.05% Tween (PBS-T). Sera were
added in serial dilutions, starting at a 1/100 dilution to each well,
and incubated for 45 min at room temperature (RT). After a washing with
PBS-T, HRP-conjugated goat anti-mouse IgG (
-chain specific,
Sigma, St. Louis, MO) was added and incubated for 45 min. After
additional washing, substrate solution containing
3,3',5,5'-tetramethylbenzidene (TMB, Sigma) was added in 0.1 M citrate
buffer, pH 4, and 0.015%
H2O2. After incubation for
30 min, absorption at OD380 was determined on a
Flow microtiter plate reader (Dynatech, McLean, VA). Results are shown
as the OD380 absorbance at a 1/100 dilution.
dsDNA was derived by S1 nuclease (Sigma)
treatment.
Isolation of cryoglobulins from sera
Cryoglobulins were isolated from sera as previously described (39). Briefly, blood samples were placed at 37°C for 2 h. After centrifugation at 1000 rpm, supernatants were collected and placed at 4°C for 72 h. They were then centrifuged at 3000 rpm, supernatants were removed, and precipitates were washed five times with cold PBS. After being washed, they were resuspended in PBS at the same volume as the original sera. The isolated cryoglobulins were placed at 37°C for 3 h before use to ensure resolubilization.
Total Ig
Total IgG levels in sera or in cryoglobulins were determined by
ELISA using a standard curve of known concentrations of mouse IgG.
Cryoglobulins were placed at 37°C for 3 h before use. ELISA
plates were coated with 1 µg/ml anti-mouse 
overnight at
4°C. Sera or cryoglobulins were added in serial dilutions starting at
a 1/1000 dilution. HRP-conjugated goat anti-mouse IgG
(-specific, Sigma) was added, followed by TMB for color development.
OD380 absorbance was measured as above. The same
method was used for measurement of serum Ig isotype levels and total Ig
in serum and in cryoglobulins except HRP goat anti-mouse IgG1,
IgG2a, or IgG3 or HRP goat anti-mouse H & L chain were used
(Southern Biotechnology, Birmingham, AL).
Measurement of circulating ICs
Circulating ICs were determined by the C1q ELISA method as
previously described with minor modifications (40). ELISA
plates were coated with human C1q in 0.1 M carbonate buffer (pH 9.6)
and incubated for 48 h at 4°C. After a washing with PBS, PBS-1%
BSA was added to each well and incubated for 2 h at RT.
EDTA-treated sera samples (diluted 1/50) were added in duplicate and
then incubated for 1 h at RT and then overnight at 4°C. HRP
anti-mouse IgG (-chain specific, Sigma) was added in PBS-T. The
rest of the assay was performed as described above. Aggregated human
-globulin was used as a positive control.
Rheumatoid factor
RF concentrations in sera were measured by ELISA as previously
described (33). ELISA plates were coated with rabbit IgG
(1 µg/ml) overnight at 4°C. After a washing, sera were added in
serial dilution starting at 1/100 dilution. The assay was then
performed as described above with HRP-conjugated goat anti-mouse
IgG (-chain specific, Sigma) or goat anti-mouse IgM (Sigma). For
the measurement of IgG3 anti-IgG2a RF, the same method was used
except ELISA plates were coated with mouse IgG2a and HRP anti-mouse
IgG3 was used for detection of RF activity.
Measurement of C3 levels in sera
C3 levels in sera were measured by ELISA. ELISA plates (with 96 wells) were coated with goat anti-mouse C3 (Cappel, Durham, NC) and incubated overnight at 4°C. After washing and blocking with 5% BSA in PBS for 1–2 h, samples diluted 1/200, 1/1,000, 1/5,000, and 1/25,000 were added to individual wells and incubated for 1–2 h at RT. After a washing, rat anti-mouse C3 mAb (RmC11H9) was added and incubated for 1 h at RT (28). Peroxidase-conjugated anti-rat IgG was added and then incubated for 1 h at RT. 2,2'-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) (1 mM) in 0.1 M citric acid buffer and 0.03% H2O2 was added for color development. The plates were read on an ELISA reader at OD405.
Measurement of Bf levels in sera
Factor B levels were measured by ELISA. ELISA plates were coated with goat anti-human factor B IgG fraction (DiaSorin, Stillwater, MN) overnight at 4°C. Sera diluted to 1/100, 1/200, and 1/400 were added to individual wells. Biotinylated anti-human Bf Ab (Diasorin) was added followed by avidin-peroxidase. TMB was added for color development. After incubation for 30 min, OD380 absorption was determined.
Pathology
At the time of sacrifice (22 and 44 wk), the kidneys were removed. One kidney was fixed with formaldehyde, embedded in paraffin, and then sectioned before staining with hematoxylin and eosin (H&E) and periodic acid-Schiff (PAS). The slides were read and interpreted in a blinded fashion, grading the kidneys for glomerular inflammation, proliferation, crescent formation, and necrosis. Interstitial changes and vasculitis were also noted. Scores from 0 to 3 were assigned for each of these features and then added together to yield a final renal score (33). For example, glomerular inflammation was graded: 0, normal; 1, few inflammatory cells; 2, moderate inflammation; and 3, severe inflammation. The other kidney was snap frozen in liquid nitrogen and placed in OCT medium. Frozen sections 4 µm thick were stained with fluorescein-conjugated anti-mouse IgG, IgM, IgA, IgG3, or C3 (Cappel, Durham, NC). Slides were read in a blinded fashion and graded 0–3+ (1+, mild staining; 2+, moderate staining; 3+, high staining).
Statistics
Statistical values were determined by using the Mann-Whitney two-tailed U test or Kruskal-Wallis test. A p value <0.05 was considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
To determine the role of Bf in autoimmune nephritis, Bf knockout
mice were backcrossed for four generations to MRL/lpr
mice. F4 B+/- mice were then intercrossed to
yield the cohorts for these studies. The genotype of the mice was
determined by PCR for Bf and Fas. The percentage of offspring in the
litters derived were consistent with the predicted outcome; i.e.,
25% of pups were either homozygous knockout
(B-/-, n = 11) or wild type
(B+/+, n = 14), whereas 50% were
heterozygous for B- (n = 20).
Ten B+/- mice were randomly selected as the
study mice. There were no differences in spleen weight or body weight
between groups at 22 or 44 wk of age (data not shown). By gross
examination at the time of sacrifice, 100% of female
B+/+ mice (7 of 7) had an excoriated skin rash on
the shoulder area as well as tail and ear necrosis; 1 of 7 male
B+/+ mice had ear and tail necrosis. Neither skin
rash nor appendage necrosis was observed in
B-/- or B+/- mice. These
skin lesions are secondary to small vessel vasculitis (41, 42).
H-2 expression
To assess the MHC expression by each group, H-2 expression of splenocytes was assessed by flow cytometry. The MRL/lpr Bf-deficient mice were H-2Db; the Bf heterozygotes H-2Db, k, and the wild-type mice were H-2Dk. PCR RFLP analysis of MHC class II genotype confirmed the H-2 haplotype of the mice: B-/- mice were H-2b; B+/- mice were H-2b/k; and B+/+ mice were H-2k.
Bf levels in sera
Bf levels in sera were measured by ELISA when the mice were 22 wk
of age. As shown in Table I
, no Bf was
detected in the sera of B-/- mice, confirming
that the phenotype of the mice matched the genotype. Serum Bf levels of
B+/+ mice were significantly higher than that of
B+/- mice (p 
0.05),
indicating a gene dose effect on serum Bf levels.
|
To assess the role of Bf in autoimmune nephritis, we measured 24-h
urine protein excretion beginning at 12 wk of age. As shown in Fig. 1, there was a statistically significant
difference in proteinuria comparing B+/- mice
after 20 wk of age (p 0.05) to both
B+/+ mice and B-/- mice,
indicating the development of early severe disease in the heterozygous
mice. The B+/+ mice developed increasing
proteinuria after 26 wk of age that was significantly greater than that
in the B-/- mice (p
0.05). Even at 44 wk of age, B-/- mice still
had not developed proteinuria >1 mg/mouse/day (data not shown).
|
A group of mice were sacrificed at the age of 22 wk (5
B-/-, 7 B+/+, and 3
B+/- mice), and pathologic renal scores were
determined using a previously published scale for glomerular
inflammation (33). The remaining
B+/+ and B-/- mice were
sacrificed at 44 wk (all B+/- mice had died or
were sacrificed before 25 wk). As shown in Fig. 2A, Bf-deficient mice had
lower renal scores than the mice in the other groups at both 22 and 44
wk. The renal abnormalities in the MRL/lpr
B-/- mice consisted of focal glomerular
hypercellularity without significant infiltrate of inflammatory cells
(Fig. 2B). Glomerular wire loop lesions, immune complex
deposition, and glomerular hyalinization, as determined by intensity of
PAS staining, were minimally present in the
B-/- mice (Fig. 2C). Renal findings
in the MRL/lpr B+/- (data not
shown) and B+/+ mice included diffuse glomerular
hypercellularity, wire loop lesions, mesangial expansion, crescent
formation, fibrinoid necrosis, glomerular hyalinization, and
infiltration of inflammatory cells (Fig. 2, D and
E). The difference in renal scores in the
B-/- compared with the other two groups at 22
wk was not statistically significant (p = 0.13)
due to severe disease in one male B-/- mouse
with a renal score similar to that seen in the other two groups. We
included the renal score of this mouse in the overall score and
statistical analysis even though it exceeded the mean of the
scores of the other B-/- mice by 6 SDs. To
ensure that this mouse had been genotyped correctly, spleen DNA was
amplified and results of the PCR amplification confirmed the
B-/- genotype of the mouse. If the score for
this mouse is excluded, the difference in renal score between the
B-/- mice and either of the other two groups
was significant at p 0.01. The difference in renal
scores between the B-/- mice and
B+/+ mice was significant at 44 wk
(p = 0.04).
|
To determine the effects of Bf genotypes on glomerular IC
deposition, immunofluorescence analysis was performed. Frozen sections
were stained with fluorescein-conjugated anti-mouse C3, IgG, IgG3,
IgM, and IgA. C3, IgM, and IgA deposition were similar in all
groups with no apparent qualitative or quantitative differences (data
not shown). Glomerular IgG3 deposition was minimal in all three groups.
There was, however, significantly less IgG deposition in
B-/- than in B+/+ mice
(p 0.05, Table II). IgG deposition in the kidneys of
B-/- mice was also less than in the
B+/- mice; the difference, however, did not
reach statistical significance (Table II).
|
Medium to large vessel vasculitis is a pathologic feature of renal
disease in MRL/lpr mice (41). At the age of
22 wk, of the 5 B-/- mice examined, only the
male B-/- mouse with severe renal disease had
vasculitis (1 of 5). Of female B+/+ mice 50% (2
of 4) had vasculitis as illustrated in Fig. 2
F, whereas no
vasculitis was present in male B+/+ mice (0 of
3). In the B+/- mice, 1 of 3 of the mice had
vasculitis; all 3 B+/- mice studied were
females. At the age of 44 wk, 100% of female
B+/+ mice had vasculitis (3 of 3). There was no
vasculitis in male B+/+ mice (0 of 4) or
vasculitis observed in the 6 B-/- mice (3 males
and 3 females). These data indicate a greater incidence of vasculitis
in the B+/+ mice than in the
B-/- mice (overall 1 of 11
B-/- mice had vasculitis compared with 5 of 14
B+/+ mice). This difference in incidence of
vasculitis was especially evident in female mice where 0 of 6 female
B-/- mice had vasculitis compared with 5 of 7
female B+/+ mice (p
0.01). The presence of renal vasculitis in the female
B+/+ mice paralleled the vasculitis induced ear
and tail necrosis present also primarily in the female
B+/+ mice.
Measurement of serum anti-DNA Ab activity
To investigate possible mechanisms for the modulation of renal
disease in the B-/- mice, we measured levels of
autoantibodies implicated in disease pathogenesis. Anti-DNA Abs are
pathogenic in the autoimmune nephritis that develops in
MRL/lpr mice (33). Anti-dsCT DNA Abs in
serum were measured by ELISA. As shown in Fig. 3, serum anti-dsCT DNA Ab levels were
lower at 16 wk of age in B-/- mice than in the
other two groups (p = 0.02). However, by 20 wk
and thereafter, the serum anti-DNA levels were not significantly
different between the groups out to 44 wk of age. Serum
anti-glomerular binding activity, as measured by ELISA, paralleled
anti-DNA activity with lower serum levels at 16 wk in the
B-/- mice that equilibrated between the groups
over time (data not shown).
|
To assess the effect of factor B on the production of other
autoantibodies in the B-/- mice, serum RF
activity was measured by ELISA. There were no detectable differences
between the groups in production of total IgM RF or IgG RF (data not
shown). However, as presented in Fig. 4,
significantly lower levels of IgG3 anti-IgG2a RF, a specificity
linked with vasculitis in these mice, were present in the sera of
B-/- mice at the age of 20 wk than in sera of
the other 2 groups (41, 42). These differences were
maintained through 44 wk.
|
MRL/lpr renal disease and vasculitis has been
linked with IgG3 cryoglobulin production (41, 42, 43, 44). To
determine whether the Bf genotype affected Ig or cryoglobulin
production, total serum Ig levels and IgG3 cryoglobulin levels were
measured by ELISA. Total IgG levels were similar at all time points in
all three groups (data not shown); however, significantly higher levels
of serum IgG3 and IgG3 cryoglobulins were present in the
B+/- and B+/+ mice
compared with the B-/- mice (Table III, Fig. 5). Serum levels of all other IgG
isotypes were not statistically different between the 3 groups (data
not shown).
|
|
To determine the effects of a lack of Bf on serum C3 levels, C3
levels were determined by ELISA at the ages of 16, 20, and 24 wk in all
three groups. As shown in Table IV, serum
C3 levels in the B-/- mice were equivalent to
levels in normal C57BL6 mice and were significantly higher than serum
C3 levels in the other two groups. Levels of serum C3 in the
B-/- mice decreased over time, suggesting some
activation of C3, but were still significantly higher than the
B+/+ mice even at 44 wk of age (data not shown).
These data imply a significant role for Bf and the alternative pathway
amplification loop in the serum C3 levels in this murine model of
immune complex renal disease.
|
To assay for effects of Bf on clearance of circulating ICs, circulating ICs were measured by ELISA using the C1q binding assay. There were no differences in sera circulating ICs between groups at any time point (data not shown).
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The mechanism by which Bf deficiency abrogates disease may involve effects on the inflammatory cascade through decreased C3 activation or direct B cell effects or a combination of both. At this time, we cannot determine which of these effects is responsible for blocking disease development in the B-/- mice, although differentiating these effects is experimentally approachable. Considering the effect of Bf deficiency on C3 activation alone, using a simplified interpretation of a complex biologic system, C3 has both "protective antiinflammatory" functions (i.e., transporting or solubilizing ICs) and "destructive proinflammatory" functions (i.e., promoting local deposition of terminal complement components and release of inflammatory mediators, i.e., C5a). Serum C3 levels represent a complex interplay of C3 production, activation, and consumption. Although we postulate that the effects of factor B deficiency on serum C3 levels are through decreased C3 activation and consumption, it is feasible that factor B deficiency may effect C3 production. The finding of decreased serum C3 activation in MRL/lpr Bf-deficient mice is consistent with similar findings noted in nonautoimmune Bf-deficient mice (36).
In lupus nephritis, the alternative pathway may enhance local tissue damage in disease via the amplification loop in which C3b, activated by IC deposition, initiates the alternative pathway feeding back on and accentuating C3 activation. In this case, the alternative pathway promotes proinflammatory complement functions including the generation of the chemotactic factor C5a. In B-/- mice, the proinflammatory functions of C3 may be diminished due to the lack of C3 activation via the amplification loop. For example, Bf deficiency may block local intrarenal inflammation by modulating levels of specific components of the complement cascade such as C5a. The lack of Bf appears to have inhibited the production of such chemotactic factors as there was minimal to no inflammatory infiltrate in the kidneys of 10 of 11 B-/- mice; inflammatory infiltrates were present in all of the kidneys from the B+/- and B+/+ mice. This lack of inflammatory mediators likely also limited the development of vasculitis in the B-/- mice.
The early decreased levels of anti-DNA Abs and the decreased deposition of IgG in the kidneys of B-deficient mice may reflect alterations in B cell function and autoantibody production in the B-/- mice. Although the overall effects of Bf on B cell function are controversial, previous studies reported stimulation of B cell proliferation and differentiation by Bf (13). In nonautoimmune Bf-deficient mice, however, no alterations in B cell proliferation or differentiation or responses to T-dependent or T-independent Ags were noted (36). In the MRL/lpr Bf-deficient mice there appears to be a possible linkage between disease severity and the B cell production of IgG3-containing cryoglobulins. Recent studies by two different groups demonstrated that IgG3 cryoglobulins are pathogenic in vasculitis and glomerulonephritis in MRL/lpr mice (39, 40, 41, 42, 43). An IgG3 mAb with anti-IgG2a RF activity derived from a MRL/lpr mouse induced skin vasculitis and glomerulonephritis when injected into normal mice (42). IgG3 cryoglobulins also induced "wire loop" lesions in glomeruli by direct glomerular deposition independent of IC deposition and complement activation (43, 44).
The low concentrations of IgG3 cryoglobulins appear directly linked to
low serum levels of total IgG3 in the MRL/lpr
B-/- mice and suggest modulation of B cell
isotype switching in Bf-deficient mice. That serum levels of IgG2a in
the B-/- mice were equivalent to the other two
groups indicates that there was no overall defect in isotype switching.
Serum IFN- levels were similar in all three genotypes (data not
shown); thus, it is unlikely that modulation of IFN- production
alone was a mechanism for the decreased sera levels of IgG3 in the
B-/- mice. Studies of the
B-/- genotype on a "normal" strain
background found no differences in B cell number, germinal center
formation, or IgG production (36). C3-deficient mice,
however, do have defects in B cell function including decreased isotype
switching and blunted responses to T-dependent Ags such as DNA and IgG
(22, 23). An indirect effect of Bf deficiency on B cell
function via decreased C3 activation may only become evident in the
setting of an activated or abnormal immune system such as occurs in
MRL/lpr mice.
Independent of effects on inflammation, complement components may also modulate autoimmune disease through indirect effects on B cells. As recently demonstrated by the Shlomchik group, B cells, independent of Ig production, play a key role in disease development in MRL/lpr mice presumably via Ag presentation (45). Complement opsonization is involved in the presentation of immune complexes by resting B cells. Thus, the lack of C3 activation in the B-/- mice may alter B cell-mediated Ag presentation resulting in a diminished autoimmune response. CD 21 can directly bind immune complexes and present them to T cells and may also augment MHC presentation of Ag; decreased complement activation may also limit this alternative mechanism of Ag presentation (46, 47).
An alternative explanation to account for disease amelioration and decreased C3 consumption in the B-/- mice is that IgA immune complexes did not activate the alternative pathway in the Bf-deficient mice (1). In Bf-producing mice, IgA ICs activate the alternative pathway leading to C3 activation (1). IgA ICs are present in the kidneys of MRL/lpr mice and patients with lupus nephritis, although their contribution to disease pathogenesis is unclear (5). Equivalent deposition of IgA in the kidneys was present in all three groups of MRL/lpr mice; however, in the B-/- mice, this deposition would not have activated the alternative complement pathway or activated C3 due to the lack of Bf. Additional studies are needed to determine the contributions of IgA IC-mediated complement activation on disease modulation in MRL/lpr mice.
An unexplained finding in these studies is the lack of a Bf dose response in many of the parameters measured; i.e., Bf heterozygous mice had an earlier onset of disease and greater proteinuria than wild-type mice. The concept of protective vs proinflammatory effects of complement in disease pathogenesis may explain why B+/- mice had worse disease than B+/+ mice (i.e., immune complex solubilization was diminished, but production of inflammatory mediators was not). Bf levels in the B+/- mice appear sufficient to activate C3 and promote inflammation as evidenced by the presence of inflammatory cells in the glomeruli and decreased serum levels of C3. The presence of IgG3 cryoglobulins in the sera of the B+/- mice suggests that the lower concentrations of Bf in these mice were sufficient for IgG3 and IgG3 cryoglobulin production. In contrast, there may not have been sufficient complement activation in the B+/- mice for adequate solubilization and clearance of immune complexes, although we have no experimental evidence indicating such a defect. We do believe, however, that the increased disease in B+/- mice is biologically relevant because we also found similar early severe renal disease in MRL/lpr C3+/- mice compared with C3+/+ and C3-/- mice (48). The similar findings of accelerated disease in both MRL/lpr B+/- mice and C3+/- mice suggest that low levels of these complement factors may be more pathogenic in IC disease than either completely absent or normal levels. The similarities of disease expression in the C3 and Bf heterozygous mice also suggest that the mechanism for accelerated disease in the B+/- mice is mediated via effects on C3.
As in all gene inactivation studies, careful consideration must be
given to alternative mechanisms for the biological effects seen in the
knockout mice. For example, the genes for Bf and C2 are contiguous on
mouse chromosome 17 (4). Although we did not specifically
measure C2 levels in the MRL/lpr
B-/- mice, studies of the
B-/- founder mice for our initial breeding
indicated normal C2 levels and function (36). A more
significant consideration in the mice in this study is the potential
effect of H-2 on disease. Although the mice in this study are 97%
homogeneous for the MRL genetic background, Bf is part of the MHC class
III locus and is thus linked to the rest of the MHC locus. Because
these mice were selected based on Bf genotype, it is likely that a
significant portion of chromosome 17, including the MHC locus, was
linked with the Bf genotype and remains of 129 genetic derivation.
H-2 affects Ag handling and peptide presentation; thus, H-2 differences could affect production of autoantibodies through alterations in Ag presentation. By spleen cell flow cytometric analysis and PCR RFLP analysis of tail DNA, the B-/- mice were H-2b. The H-2b present in the B-/- mice was derived from the original knockout construct in 129 mice. The B+/+ mice were H-2k (the H-2 of MRL/lpr mice) and the heterozygous mice were H-2b/k. H-2 and H-2 heterozygosity are known to play a major role in disease in some strains of lupus-prone mice (e.g., NZB/NZW mice) (34, 35). Such an effect of H-2 on MRL/lpr disease, however, has not been reported. In genetic linkage studies in MRL/lpr mice, H-2 is not linked with anti-DNA production, anti-glomerular Ab binding, or incidence or severity of renal disease in H-2k x H-2b crosses involving MRL/lpr mice or further backcrosses to MRL/lpr where H-2b/b mice were derived (34, 35). The only linkage between disease and H-2 in MRL (H-2b x H-2k) crosses and backcrosses is that MRL/lpr H-2b mice are higher producers of IgM and IgG RFs than MRL H-2k mice (34). We did not observe this effect in the MRL/lpr B-/- mice (data not shown). The H-2b in the factor B knockout mice was derived from 129 mice. Although the H-2b of C57BL/6 mice does not appear to affect disease expression in MRL/lpr mice, it is conceivable there are differences in the H-2b of 129 mice and factor B mice that could affect immune function. We are unaware of any reports of such differences. We cannot definitively rule out a contribution of genetic elements other than factor B to the phenotypic differences seen in the study mice. We believe, however, that the use of littermates as controls and the current data regarding effects of MHC on disease in MRL/lpr mice suggests the contributions of these other genetic elements is likely minimal.
In summary, our results suggest that: 1) Bf has an important role in the development of glomerulonephritis and vasculitis in MRL/lpr mice through direct or indirect effects on the production of specific autoantibodies, cryoglobulins and inflammatory mediators; 2) Bf and the alternative pathway amplification loop play an important role in C3 production, activation, or consumption in this model of immune complex renal disease. MRL/lpr B-/- mice thus provide a new and useful model for dissecting the role of the alternative pathway in IC- mediated diseases. Furthermore, these results suggest that Bf may be a novel specific target for therapy in IC-mediated diseases.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Gary S. Gilkeson, Medical University of South Carolina, Division of Rheumatology/Immunology, 96 Jonathan Lucas Street, Suite 912, P.O. Box 250623, Charleston, SC 29425. E-mail address:
3 Abbreviations used in this paper: Bf, complement factor B; IC, immune complex; RF, rheumatoid factors; RT, room temperature; TMB, 3,3',5,5'-tetramethylbenzidene; H&E, hematoxylin and eosin; PAS, periodic acid-Schiff; dsCT DNA, double-stranded calf thymus DNA.
Received for publication June 16, 1999. Accepted for publication November 3, 1999.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
interferon and lipopolysaccharide for synthesis of factor B, but not C2, in human fibroblasts. J. Exp. Med. 167:1. induces synthesis of complement alternative pathway proteins by human endothelial cells in culture. J. Exp. Med. 168:1917.This article has been cited by other articles:
|
|
 |
|
  K. Goring, Y. Huang, C. Mowat, C. Leger, T.-H. Lim, R. Zaheer, D. Mok, L. A. Tibbles, D. Zygun, and B. W. Winston Mechanisms of human complement factor B induction in sepsis and inhibition by activated protein C Am J Physiol Cell Physiol, May 1, 2009; 296(5): C1140 - C1150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wu, D. Spitzer, D. Mao, S. L. Peng, H. Molina, and J. P. Atkinson Membrane Protein Crry Maintains Homeostasis of the Complement System J. Immunol., August 15, 2008; 181(4): 2732 - 2740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. T. Le, G. Abbenante, and D. P. Fairlie Profiling the Enzymatic Properties and Inhibition of Human Complement Factor B J. Biol. Chem., November 30, 2007; 282(48): 34809 - 34816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Lenderink, K. Liegel, D. Ljubanovic, K. E. Coleman, G. S. Gilkeson, V. M. Holers, and J. M. Thurman The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy Am J Physiol Renal Physiol, August 1, 2007; 293(2): F555 - F564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jiang, J. Foley, N. Clayton, G. Kissling, M. Jokinen, R. Herbert, and M. Diaz Abrogation of Lupus Nephritis in Activation-Induced Deaminase-Deficient MRL/lpr Mice J. Immunol., June 1, 2007; 178(11): 7422 - 7431. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Alexander, Y. Wang, A. Chang, A. Jacob, A. W.M. Minto, M. Karmegam, M. Haas, and R. J. Quigg Mouse Podocyte Complement Factor H: The Functional Analog to Human Complement Receptor 1 J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1157 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sekine, K. L. Graham, S. Zhao, M. K. Elliott, P. Ruiz, P. J. Utz, and G. S. Gilkeson Role of MHC-Linked Genes in Autoantigen Selection and Renal Disease in a Murine Model of Systemic Lupus Erythematosus J. Immunol., November 15, 2006; 177(10): 7423 - 7434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. K. Banda, J. M. Thurman, D. Kraus, A. Wood, M. C. Carroll, W. P. Arend, and V. M. Holers Alternative Complement Pathway Activation Is Essential for Inflammation and Joint Destruction in the Passive Transfer Model of Collagen-Induced Arthritis J. Immunol., August 1, 2006; 177(3): 1904 - 1912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Taube, J. M. Thurman, K. Takeda, A. Joetham, N. Miyahara, M. C. Carroll, A. Dakhama, P. C. Giclas, V. M. Holers, and E. W. Gelfand Factor B of the alternative complement pathway regulates development of airway hyperresponsiveness and inflammation PNAS, May 23, 2006; 103(21): 8084 - 8089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Alexander, O.G.B. Aneziokoro, A. Chang, B. K. Hack, A. Markaryan, A. Jacob, R. Luo, M. Thirman, M. Haas, and R. J. Quigg Distinct and Separable Roles of the Complement System in Factor H-Deficient Bone Marrow Chimeric Mice with Immune Complex Disease J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1354 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Thurman and V. M. Holers The Central Role of the Alternative Complement Pathway in Human Disease J. Immunol., February 1, 2006; 176(3): 1305 - 1310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Meyers, M. Geanacopoulos, L. B. Holzman, and D. J. Salant Glomerular Disease Workshop J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3472 - 3476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bao, I. Osawe, M. Haas, and R. J. Quigg Signaling through Up-Regulated C3a Receptor Is Key to the Development of Experimental Lupus Nephritis J. Immunol., August 1, 2005; 175(3): 1947 - 1955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Alexander, M. C. Pickering, M. Haas, I. Osawe, and R. J. Quigg Complement Factor H Limits Immune Complex Deposition and Prevents Inflammation and Scarring in Glomeruli of Mice with Chronic Serum Sickness J. Am. Soc. Nephrol., January 1, 2005; 16(1): 52 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. K. Zhang, S. Gallant, I. Molano, O. M. Moussa, P. Ruiz, D. D. Spyropoulos, D. K. Watson, and G. Gilkeson Decreased Expression of the Ets Family Transcription Factor Fli-1 Markedly Prolongs Survival and Significantly Reduces Renal Disease in MRL/lpr Mice J. Immunol., November 15, 2004; 173(10): 6481 - 6489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Quigg Complement and the Kidney J. Immunol., October 1, 2003; 171(7): 3319 - 3324. [Full Text] [PDF]
|
|
|
|
|
|
L. Bao, M. Haas, D. M. Kraus, B. K. Hack, J. K. Rakstang, V. M. Holers, and R. J. Quigg Administration of a Soluble Recombinant Complement C3 Inhibitor Protects Against Renal Disease in MRL/lpr Mice J. Am. Soc. Nephrol., March 1, 2003; 14(3): 670 - 679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Thurman, D. Ljubanovic, C. L. Edelstein, G. S. Gilkeson, and V. M. Holers Lack of a Functional Alternative Complement Pathway Ameliorates Ischemic Acute Renal Failure in Mice J. Immunol., February 1, 2003; 170(3): 1517 - 1523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Miwa, M. A. Maldonado, L. Zhou, X. Sun, H. Y. Luo, D. Cai, V. P. Werth, M. P. Madaio, R. A. Eisenberg, and W.-C. Song Deletion of Decay-Accelerating Factor (CD55) Exacerbates Autoimmune Disease Development in MRL/lpr Mice Am. J. Pathol., September 1, 2002; 161(3): 1077 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bao, M. Haas, S. A. Boackle, D. M. Kraus, P. N. Cunningham, P. Park, J. J. Alexander, R. K. Anderson, K. Culhane, V. M. Holers, et al. Transgenic Expression of a Soluble Complement Inhibitor Protects Against Renal Disease and Promotes Survival in MRL/lpr Mice J. Immunol., April 1, 2002; 168(7): 3601 - 3607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Mitchell, M. C. Pickering, J. Warren, L. Fossati-Jimack, J. Cortes-Hernandez, H. T. Cook, M. Botto, and M. J. Walport C1q Deficiency and Autoimmunity: The Effects of Genetic Background on Disease Expression J. Immunol., March 1, 2002; 168(5): 2538 - 2543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Einav, O. O. Pozdnyakova, M. Ma, and M. C. Carroll Complement C4 Is Protective for Lupus Disease Independent of C3 J. Immunol., February 1, 2002; 168(3): 1036 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ji, D. Gauguier, K. Ohmura, A. Gonzalez, V. Duchatelle, P. Danoy, H.-J. Garchon, C. Degott, M. Lathrop, C. Benoist, et al. Genetic Influences on the End-Stage Effector Phase of Arthritis J. Exp. Med., August 6, 2001; 194(3): 321 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sekine, C. M. Reilly, I. D. Molano, G. Garnier, A. Circolo, P. Ruiz, V. M. Holers, S. A. Boackle, and G. S. Gilkeson Complement Component C3 Is Not Required for Full Expression of Immune Complex Glomerulonephritis in MRL/lpr Mice J. Immunol., May 15, 2001; 166(10): 6444 - 6451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nataf, S. L. Carroll, R. A. Wetsel, A. J. Szalai, and S. R. Barnum Attenuation of Experimental Autoimmune Demyelination in Complement-Deficient Mice J. Immunol., November 15, 2000; 165(10): 5867 - 5873. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
